CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Clinical trial NCT00142168 · TERMINATED

Trial details

NCT number: NCT00142168
Sponsor: Dana-Farber Cancer Institute
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstrom's Macroglobulinemia

Start date: 2004-09-01
Primary completion: 2006-05-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.